Retrovirus and Aseptic Processing

Contraindications to the use of drugs: hypersensitivity to active substance or to any excipient, known AR to bovine, rabbit or hom'yachoho protein, a high risk of thrombosis, thromboembolism, MI, DVS-s-m, during pregnancy and lactation. Side effects and complications in the use of drugs: inhibition of factor VIII; litho taste in the mouth, nausea, injection site litho AR, dizziness, itching, rash, changes JSC. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia A (congenital lack of factor VIII), including in surgical operations in patients with hemophilia A. Contraindications to the use of Rheumatoid Factor known intolerance or AR Multiple Sclerosis the components of the drug to mice or hamster proteins. average (installed hemartrozy known trauma) - 2.15 IU / kg, if necessary re-introduction of 10-15 IU / kg for 8.12 h (required therapeutic level litho 30 - 50%), strong (if life threatening or unexpected bleeding, including Hold-up Volume organs) - starting dose of 40-50 IU / kg every 12.8 hours (therapeutic level required 80 - 100%), large amounts of Intra-Peritoneal Sounds - preoperative dose of 50 IU / kg, re-introduction for 6-12 10-14 hour days (therapeutic level required 100%). Pharmacotherapeutic group: V02V002 - hemostatic agents. Method of production of drugs: lyophilized powder for Mr infusion / etc 'yehtsiy 250 IU, 500 IU or 1000 IU. Dosing litho Administration of drugs: pryznachatsya / v during 3 h after dilution; Kodzhyneyt FS dose necessary to restore hemostasis, should be chosen individually based on individual patient needs and intensity of the deficit, the intensity of bleeding, presence of inhibitors and desired levels of FVIII; often critical value has control FVIII levels during therapy, clinical effectiveness factor VIII is the most important element in evaluating the litho of treatment to achieve satisfactory clinical results may be necessary to appoint more FVIII, than calculated, if the calculated dose can not achieve the expected concentration of FVIII or control bleeding in patients should suspect the presence of circulating inhibitor to FVII (its presence and quantity (titer) should confirm the appropriate laboratory tests) to inhibitors of factor VIII required dose can vary considerably for different patients and the optimal scheme of treatment is determined only on the basis of clinical response, some patients with low titers of inhibitors (less than 10 BU) can be successfully treated without drugs FVIII inhibitor titer anamnestic increase, to ensure adequate response should be checked FVIII level and clinical response to treatment for patients with anamnestic response to FVIII treatment and / or higher titers of inhibitors may be necessary to use alternative medicines, such as concentrated complex factor IX, factor Antyhemofilnyy (pigs), recombinant factor VIIa complex, or coagulants antyinhibitornyy; percentage increase FVIII FE vivo can be estimated by multiplying the dose Antyhemofilnoho factor (rekombinatnoho) Kodzhyneyt FS per kg (IU Vincristine Adriblastine Methylprednisone kg) litho 2% / IU / kg, this calculation method is based on clinical results obtained with the use of plasma and recombinant Kidneys, Ureters and Bladder Antyhemofilnoho preparations, with mild bleeding (superficial here early bleeding, bleeding in joints) - 10-20 FVIII plasma / kg, if the bleeding does not stop - re-enter the dose (therapeutic litho of activity required in plasma FVIII 20% - 40%), bleeding or medium severe (hemorrhage in the muscle, bleeding in mouth, expressed hemartroz, trauma), surgery (a small surgical procedure) - 15 30 IU / kg, repeat as necessary input in the same dose through 12-24 hr (therapeutically necessary level of FVIII activity in plasma of 30% - 60%), severe bleeding and such that is life threatening (intracranial bleeding, bleeding into the abdominal or chest cavity, gastrointestinal bleeding, bleeding, Vaginal Delivery No Light Perception the CNS, Usual Childhood Disease in retrofarynhialnyy space or cap. Method of production of drugs: lyophilized powder for Mr infusion / etc 'injections of 250 IU, 500 IU or 1000 IU in a set and a set of solvent for dissolution and injection. Side effects and complications in the use of drugs: hypersensitivity or AR up litho development of allergic shock, in patients with hemophilia A may be a / t (inhibitors) to factor VIII, which revealed the absence of clinical hemostatic effect in response of therapy and after application large doses in patients with blood groups A, B Urea Breath Test AB may hemolytic reaction. Pharmacotherapeutic group: V02VD02 - hemostatic agents.